- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03271307
Use of HIV Self-Test Kits to Increase Identification of HIV-Infected Individuals and Their Partners
This study comprises two trials to evaluate the feasibility and cost-effectiveness of HIV self-testing strategies compared to standard of care among clients in outpatient departments (OPD; Aim 1) and the sexual partners of HIV-positive clients (index testing; Aim 2).
Aim 1 will be a cluster-randomized trial in 15 clusters (high-burden health facilities) in Malawi. We will enroll 6,000 adult OPD clients (15 years or older) to test the feasibility and cost-effectiveness of facility-based HIV self-testing (HIVST) for OPD clients.
Aim 2 will be an individually-randomized trial in 3 high-burden health facilities in Malawi. We will enroll 500 adult HIV-positive clients (15 years or older) to test the feasibility and cost-effectiveness of index HIVST among partners of HIV-positive clients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study includes two unblinded trials to evaluate the feasibility and cost-effectiveness of HIVST strategies among adults in Malawi.
Aim 1 will test the feasibility and cost-effectiveness of facility-based HIVST in OPD sites in Malawi. It will be an unblinded cluster-randomized trial and include three arms: 1) standard of care for provider-initiated testing and counseling (PITC); (2) optimized standard of care for PITC; and (3) facility-based HIVST while clients wait for routine OPD services. The standard of care arm will receive no intervention. The optimized standard of care arm will receive training and support for implementing the Malawi guidelines for PITC and morning testing. OPD clients in the facility HIVST arm will receive a HIVST demonstration and distribution, followed by uses of HIVST and private spaces for kit interpretation before receiving routine OPD services. Participants may present their self-test results to their provider, who will refer them for confirmatory HIV testing and routine ART initiation (if positive). That same day, participants from all arms will complete a brief survey upon exiting the clinic. Survey and medical record data will be compared across arms to determine whether facility HIVST is superior in regard to number of individuals tested for HIV, cost-effectiveness, number of HIV-positive individuals identified, and linkage rates for those who identify as HIV-positive.
Aim 2 will test the feasibility and cost-effectiveness of index HIVST for the sexual partners of HIV-positive clients. It will be an unblinded individually-randomized trial and include two arms: 1) standard of care partner referral slips for testing; and 2) HIVST. The standard of care arm will receive no intervention for partner notification and referral. HIV-positive clients in the HIVST arm will receive a HIVST demonstration and distribution, with instructions to give the HIVST kit to their sexual partner. Participants will be given one HIVST for each of their sexual partners who has an unknown HIV status or who tested HIV-negative more than six months prior (up to 3 HIVST kits distributed). Participants (index clients) will be given instructions on how their partner can complete the self-test and how to refer their partner(s) to care if they receive a positive result from the self-test. All participants (standard of care and HIVST arms) will complete a brief survey at the beginning of the intervention and a 4-week follow-up survey to assess primary and secondary outcomes. Medical chart reviews will be conducted for all partners reported to test HIV-positive in order to assess ART initiation rates. Survey and medical record data will be compared across arms to determine whether index HIVST is superior in regard to number of partners tested for HIV, cost-effectiveness, number of HIV-positive individuals identified, and linkage rates for those who identify as HIV-positive.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lilongwe, Malawi
- Partners in Hope
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 15 years or older
- Willing and able to provide informed consent
- Being seen for OPD services at the time of the study (Aim 1)
- HIV-positive (Aim 2)
- Have at least one sex partner in the catchment area with an unknown HIV status at the time of study enrollment (Aim 2)
Exclusion Criteria:
- Currently enrolled in the INTERVAL study
- Guardians attending clinics with OPD clients (Aim 1)
- History of intimate partner violence in the past 12 months (Aim 2)
- Fear of intimate partner violence as a consequence of participating in the study (Aim 2)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: AIm 1: Standard of care
Facilities assigned to the standard of care arm will receive no intervention and will continue with Ministry of Health National HIV Guidelines for provider-initiated testing and counseling (PITC) for outpatients in Aim 1. PITC guidelines recommend providers inform their OPD clients about HIV testing and refer them to HIV testing services at the facility.
|
|
EXPERIMENTAL: Aim 1: Optimized standard of care
Facilities assigned to the optimized standard of care arm will receive additional guidance and support from the study team to adopt the Ministry of Health National HIV Guidelines for provider-initiated testing and counseling (PITC) for Aim 1.
|
Providers will receive training on the importance of HIV testing and their role in testing as part of OPD care and morning HIV testing will be offered.
Providers will receive job aids on the importance of referring patients for HIV testing, and the study team will conduct regular monitoring and evaluation on PITC implementation.
Other Names:
|
EXPERIMENTAL: Aim 1: Facility HIVST
Facilities assigned to the HIVST arm will implement HIVST procedures in lieu of recommendations provided by the Ministry of Health National HIV Guidelines (PITC).
|
HIVST will be carried out in a group setting among patients in the waiting area of OPD clinics.
Eligible clients will receive education about HIV testing and a demonstration of how to use and interpret results of a self-test kit will occur in the group setting.
Participants will use the HIVST kit in a group setting and will be given private settings (private room or booth) to interpret their results.
Participants will disclose their results to their OPD provider if they choose.
Routine linkage to confirmatory testing and ART initiation will be conducted.
|
NO_INTERVENTION: Aim 2: Standard of care
Facilities assigned to the standard of care arm will receive no intervention and will continue with Ministry of Health National HIV Guidelines for index HIV testing for sexual partners of HIV-positive clients.
Partner referral slips will be given to HIV-positive clients to encourage partner testing.
|
|
EXPERIMENTAL: Aim 2: Index HIVST
Facilities assigned to the HIVST arm will implement HIVST procedures in lieu of recommendations provided by the Ministry of Health National HIV Guidelines (partner referral slips).
|
HIVST demonstration and distribution will be provided to HIV-positive clients in participating facilities to distribute to their partners.
Partners who have a reactive HIVST test result, or are unable or unwilling to use HIVST, will be asked to present at the health facility for routine HIV testing.
Routine linkage to confirmatory testing and ART initiation will be conducted.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Aim 1: Proportion of Adult OPD Clients Tested for HIV
Time Frame: 1 day
|
Same day HIV testing among OPD clients, measured by self-reports from OPD clients
|
1 day
|
Aim 2: Proportion of Sexual Partners Tested for HIV
Time Frame: 4-weeks
|
HIV testing among sexual partners of HIV-positive clients within 4-weeks of study enrollment, measured by secondary reports from HIV-positive clients
|
4-weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Aim 1: HIV-positivity Rate
Time Frame: Same 1 day as enrollment (measuring HIV testing before clients leave the OPD clinic that day)
|
HIV-positivity rate among OPD clients, measured by self-report
|
Same 1 day as enrollment (measuring HIV testing before clients leave the OPD clinic that day)
|
Aim 1: ART Initiation Among OPD Clients Tested HIV-positive
Time Frame: 3 months
|
ART initiation within 3-months after being identified as HIV-positive within the study, measured by medical chart reviews of all Partners in Hope supported health facilities in participating districts
|
3 months
|
Aim 1: Presence of Non-serious Adverse Events
Time Frame: as enrollment (measuring adverse events that occurred at the OPD clinic that 1 day)
|
Presence of adverse events due to the HIV testing intervention, including coercion to test, share test results, and unwanted status disclosure, measured by self-report on the day the intervention was delivered.
|
as enrollment (measuring adverse events that occurred at the OPD clinic that 1 day)
|
Aim 1: Cost Per Person Initiated ART
Time Frame: 3 months
|
Total cost per arm (including human resources, testing, training, equipment, facility over head, staff, and testing supplies) / total number of individual initiated ART by each arm, respectively.
All costs in 2017 US$.
Cost calculations do not include cost of ART.
Cost data in each study group were derived from a health care perspective using micro-costing methods using the HIV Counselling and Testing costing tool developed by the Health Economics and Epidemiology Research Office in South Africa.
All costs are reported in 2017 US$.
We use mean cost per ART initiate.
Standard deviation is not included due to the nature of calculating a 'production cost'- or the total cost incurred per the respective number of outcomes.
|
3 months
|
Aim 2: HIV-positivity Rates Among Sexual Partners Tested for HIV
Time Frame: 4-weeks
|
HIV-positivity rate measured by secondary report by the HIV-positive client
|
4-weeks
|
Aim 2: ART Initiation Among Sexual Partners Tested HIV-positive
Time Frame: 3 months
|
ART initiation within 3-months after being identified as HIV-positive within the study, measured by medical chart reviews of all Partners in Hope supported health facilities in participating districts
|
3 months
|
Aim 2: Presence of Non-serious Adverse Events
Time Frame: 4-weeks
|
Presence of adverse events due to the HIV testing intervention, including coercion to test, share test results, unwanted status disclosure, and interpersonal violence measured by self-report by the HIV-positive client
|
4-weeks
|
Aim 2: Cost Per Person Tested HIV-Positive
Time Frame: 1 month
|
Total cost per arm (including human resources, testing, training, equipment, facility over head, staff, and testing supplies) / total number of individual tested HIV-positive by each arm, respectively.
All costs in 2017 US$.
Cost calculations include all costs associated with HIV testing.
Cost data in each study group were derived from a health care perspective using micro-costing methods using the HIV Counselling and Testing costing tool developed by the Health Economics and Epidemiology Research Office in South Africa.
All costs are reported in 2017 US$.
We use mean cost per HIV-positive individual identified.
Standard deviation is not included due to the nature of calculating a 'production cost'- or the total cost incurred per the respective number of outcomes.
|
1 month
|
Aim 2: Cost Per Person Initiated ART
Time Frame: 3 month
|
Total cost per arm (including human resources, testing, training, equipment, facility over head, staff, and testing supplies) / total number of individual initiated ART by each arm, respectively.
All costs in 2017 US$.
Cost calculations do not include cost of ART.
Cost data in each study group were derived from a health care perspective using micro-costing methods using the HIV Counselling and Testing costing tool developed by the Health Economics and Epidemiology Research Office in South Africa.
All costs are reported in 2017 US$.
We use mean cost per ART initiate.
Standard deviation is not included due to the nature of calculating a 'production cost'- or the total cost incurred per the respective number of outcomes.
|
3 month
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Kathryn Dovel, PhD, MPH, University of California, Los Angeles
Publications and helpful links
General Publications
- Mphande M, Campbell P, Hoffman RM, Phiri K, Nyirenda M, Gupta SK, Wong V, Dovel K. Barriers and facilitators to facility HIV self-testing in outpatient settings in Malawi: a qualitative study. BMC Public Health. 2021 Dec 2;21(1):2200. doi: 10.1186/s12889-021-12213-6.
- Dovel K, Shaba F, Offorjebe OA, Balakasi K, Nyirenda M, Phiri K, Gupta SK, Wong V, Tseng CH, Nichols BE, Cele R, Lungu E, Masina T, Coates TJ, Hoffman RM. Effect of facility-based HIV self-testing on uptake of testing among outpatients in Malawi: a cluster-randomised trial. Lancet Glob Health. 2020 Feb;8(2):e276-e287. doi: 10.1016/S2214-109X(19)30534-0. Erratum In: Lancet Glob Health. 2020 Mar;8(3):e340.
- Dovel K, Shaba F, Nyirenda M, Offorjebe OA, Balakasi K, Phiri K, Nichols B, Tseng CH, Bardon A, Ngona K, Hoffman R. Evaluating the integration of HIV self-testing into low-resource health systems: study protocol for a cluster-randomized control trial from EQUIP Innovations. Trials. 2018 Sep 17;19(1):498. doi: 10.1186/s13063-018-2878-y.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-000109
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Optimized PITC
-
Biotronik, Inc.CompletedCongestive Heart FailureSwitzerland, United States
-
University of Medicine and Pharmacy at Ho Chi Minh...CompletedMajor Depressive DisorderVietnam
-
University Hospital, BordeauxCompletedMyocardial Infarction | StrokeFrance
-
University Hospital, CaenRecruiting
-
Centre Hospitalier Intercommunal de Toulon La Seyne...Hamilton Medical AGRecruitingAcute Respiratory FailureFrance
-
Carlo ChiesaAssociazione Italiana per la Ricerca sul CancroRecruitingMetastatic Differentiated Thyroid CancerItaly
-
University of CopenhagenHerlev and Gentofte HospitalCompletedQuality of Life | Nutritional Deficiency | Physical PerformanceDenmark
-
Chongqing University Cancer HospitalRecruitingNasopharyngeal Carcinoma by AJCC V8 StageChina
-
Beijing Aerospace General HospitalCompletedPulmonary Nodule, SolitaryChina
-
University Hospital, MontpellierCompletedAdverse Drug EventFrance